Pharmacogenetics of efavirenz and central nervous system side effects: an Adult AIDS Clinical Trials Group study.

Mixed-Effects Models in S and S-PLUS

2001 • 9,637 citations

Declining Morbidity and Mortality among Patients with Advanced Human Immunodeficiency Virus Infection

1998 • 9,382 citations

P450 superfamily: update on new sequences, gene mapping, accession numbers and nomenclature

1996 • 2,895 citations

Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians.

1994 • 2,716 citations

Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression

2001 • 2,120 citations

Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications

1999 • 1,263 citations

The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitors.

1998 • 1,058 citations

Efavirenz plus Zidovudine and Lamivudine, Efavirenz plus Indinavir, and Indinavir plus Zidovudine and Lamivudine in the Treatment of HIV-1 Infection in Adults

1999 • 1,008 citations

Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1-infected patients

2001 • 828 citations

Response to antiretroviral treatment in HIV-1-infected individuals with allelic variants of the multidrug resistance transporter 1: a pharmacogenetics study

2002 • 670 citations

The Cytochrome P450 2B6 (CYP2B6) Is the Main Catalyst of Efavirenz Primary and Secondary Metabolism: Implication for HIV/AIDS Therapy and Utility of Efavirenz as a Substrate Marker of CYP2B6 Catalytic Activity

2003 • 582 citations

Extensive genetic polymorphism in the human CYP2B6 gene with impact on expression and function in human liver.

2001 • 566 citations

Ultrarapid hydroxylation of debrisoquine in a Swedish population. Analysis of the molecular genetic basis.

1995 • 310 citations

Characterization of the in vitro biotransformation of the HIV-1 reverse transcriptase inhibitor nevirapine by human hepatic cytochromes P-450.

1999 • 272 citations

Population pharmacokinetics and effects of efavirenz in patients with human immunodeficiency virus infection

2003 • 268 citations

Bupropion and 4-OH-bupropion pharmacokinetics in relation to genetic polymorphisms in CYP2B6

2003 • 248 citations

Human cytochrome P4502B6: interindividual hepatic expression, substrate specificity, and role in procarcinogen activation.

1997 • 245 citations

Stereoselective metabolism of methadone N‐demethylation by cytochrome P4502B6 and 2C19

2003 • 229 citations

Disposition and biotransformation of the antiretroviral drug nevirapine in humans.

1999 • 216 citations

Smoking, alcoholism and genetic polymorphisms alter CYP2B6 levels in human brain

2003 • 205 citations

THE ROLE OF CYP2B6 IN HUMAN XENOBIOTIC METABOLISM*

1999 • 169 citations

Functional Characterization of Cytochrome P450 2B6 Allelic Variants

2003 • 150 citations

A Single Nucleotide Polymorphism of CYP2B6 Found in Japanese Enhances Catalytic Activity by Autoactivation

2001 • 141 citations

Human thiopurine methyltransferase pharmacogenetics. Kindred with a terminal exon splice junction mutation that results in loss of activity.

1998 • 118 citations

Role of P450IID6, the target of the sparteine-debrisoquin oxidation polymorphism, in the metabolism of imipramine

1991 • 114 citations

Simultaneous determination of nine antiretroviral compounds in human plasma using liquid chromatography

2003 • 90 citations

Population pharmacokinetic meta-analysis with efavirenz

2002 • 87 citations

A Multi-Investigator/Institutional DNA Bank for AIDS-Related Human Genetic Studies: AACTG Protocol A5128

2003 • 65 citations

MDR1 Gene Polymorphisms and Phase 1 Viral Decay During HIV-1 Infection

2003 • 57 citations